Form 8-K - Current report:
SEC Accession No. 0001628280-22-013956
Filing Date
2022-05-12
Accepted
2022-05-12 08:00:47
Documents
14
Period of Report
2022-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20220512.htm   iXBRL 8-K 38998
2 EX-99.1 a991pressreleasedatedmay12.htm EX-99.1 82741
6 x4logoa.jpg GRAPHIC 9468
  Complete submission text file 0001628280-22-013956.txt   285237

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20220512.xsd EX-101.SCH 1908
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20220512_lab.xml EX-101.LAB 25948
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20220512_pre.xml EX-101.PRE 13681
8 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20220512_htm.xml XML 11883
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 22915766
SIC: 2836 Biological Products, (No Diagnostic Substances)